SEC Form 4 · accession 0001209191-18-056075
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Bahrt
Officer — Chief Medical Officer
Period of report
Oct 22, 2018
Accepted (ET)
Oct 24, 2018 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.90 | Oct 22, 2018 | A | 450,000 | A | — | Oct 22, 2028 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1The shares underlying the option shall vest in four equal installments beginning on October 22, 2019 such that the option shall be vested in full on October 22, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in certain circumstances as provided in the Issuer's 2015 Equity Incentive Plan.